XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenues:    
Total revenues $ 8,584 $ 19,815
Operating Expenses:    
Research and development 38,893 44,831
General and administrative 10,778 9,995
Restructuring charge 559 1,731
Total operating expenses 50,230 56,557
Loss from operations (41,646) (36,742)
Investment income, net 1,422 662
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes (3,432) (3,046)
Interest expense on convertible senior notes (24) (24)
Other (expense) income, net (71) 537
Net loss $ (43,751) $ (38,613)
Basic and diluted net loss per common share (in dollar per share) $ (0.30) $ (0.30)
Basic and diluted weighted average common shares outstanding (in shares) 147,813 130,619
Total comprehensive loss $ (43,751) $ (38,613)
License and milestone fees    
Revenues:    
Total revenues 79 11,540
Non-cash royalty revenue related to the sale of future royalties    
Revenues:    
Total revenues 8,488 7,190
Research and development support    
Revenues:    
Total revenues $ 17 383
Clinical materials revenue    
Revenues:    
Total revenues   $ 702